Xbrane Biopharma AB’s annual report for 2021 is now available at the company’s website, www.xbrane.com. The annual report includes the corporate governance report and the sustainability report for 2021.

The annual report is distributed to the shareholders and others that made such request. The annual report can also be ordered from Xbrane Biopharma on the following address:

Xbrane Biopharma AB
Retzius väg 8
171 65 Solna
Sweden
Or via e-mail: ir@xbrane.com

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-03-31 18:30 CEST.

Attachments

Xbrane Annual Report 2021
Xbrane Biopharma ESEF reporting 2021

© Modular Finance, source Nordic Press Releases